CervoMed Inc. (CRVO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CervoMed Inc. (CRVO) has a cash flow conversion efficiency ratio of -0.301x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.92 Million) by net assets ($22.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CervoMed Inc. stock valuation for the company's overall valuation and market capitalisation.
CervoMed Inc. - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how CervoMed Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
CervoMed Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CervoMed Inc. ranked by their cash flow conversion efficiency. Explore CervoMed Inc. cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Domiki Kritis S.A.
AT:DOMIK
|
0.028x |
|
BioSmart Co.Ltd
KQ:038460
|
0.042x |
|
Danhua Chemical Technology Co Ltd B
SHG:900921
|
0.035x |
|
Shandong Chenming Paper Holdings Limited
F:SCD1
|
0.823x |
|
Müller - Die lila Logistik AG
XETRA:MLL
|
0.043x |
|
Taekyung Chem
KO:006890
|
0.014x |
|
BYC Co Ltd
KO:001465
|
0.006x |
|
Gemvaxlink Co. Ltd
KQ:064800
|
0.009x |
Annual Cash Flow Conversion Efficiency for CervoMed Inc. (1998–2025)
The table below shows the annual cash flow conversion efficiency of CervoMed Inc. from 1998 to 2025. View CervoMed Inc. stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.22 Million | $-23.45 Million | -1.287x | -205.17% |
| 2024-12-31 | $39.20 Million | $-16.53 Million | -0.422x | +58.25% |
| 2023-12-31 | $7.38 Million | $-7.45 Million | -1.010x | -453.20% |
| 2022-12-31 | $-9.00 Million | $-2.57 Million | 0.286x | +168.83% |
| 2021-12-31 | $34.91 Million | $-14.50 Million | -0.415x | +23.94% |
| 2020-12-31 | $24.81 Million | $-13.55 Million | -0.546x | -11.55% |
| 2019-12-31 | $20.13 Million | $-9.86 Million | -0.490x | +29.04% |
| 2018-12-31 | $15.61 Million | $-10.77 Million | -0.690x | -18.79% |
| 2017-12-31 | $21.23 Million | $-12.33 Million | -0.581x | +50.45% |
| 2016-12-31 | $9.18 Million | $-10.77 Million | -1.172x | -100.94% |
| 2015-12-31 | $-41.62K | $-5.19 Million | 124.578x | +52752.75% |
| 2014-12-31 | $38.17 Million | $-9.03 Million | -0.237x | -29.13% |
| 2013-12-31 | $6.47 Million | $-1.18 Million | -0.183x | -178.24% |
| 2012-12-31 | $-18.41 Million | $-4.31 Million | 0.234x | -68.84% |
| 2011-12-31 | $-16.00 Million | $-12.02 Million | 0.751x | +100.77% |
| 2010-12-31 | $20.22K | $-1.98 Million | -97.964x | -4474.39% |
| 2009-12-31 | $493.60K | $-1.06 Million | -2.142x | -85.81% |
| 2008-12-31 | $438.99K | $-505.95K | -1.153x | +61.74% |
| 1999-12-31 | $2.77 Million | $-8.35 Million | -3.012x | -133.32% |
| 1998-12-31 | $5.50 Million | $-7.10 Million | -1.291x | -- |
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood"brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and sl… Read more